| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two podium presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference (TCT 2025) being held October 25-28, 2025 in San Francisco, CA.
The presentations will highlight positive results from the initial phase of Autonomix's first-in-human proof-of-concept clinical study evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
Posted In: AMIX
